Bayer buys Algeta

Bayer is ponying up $2.9 billion to buy now-former oncology partner Algeta, reports PMLive. The deal means Bayer will own the prostate cancer therapy Xofigo outright.

The company previously estimated the alpha-particle-emitting therapeutic agent would hit $1.3 billion in annual sales.

The FDA approved the treatment in May.

You must be a registered member of MMM to post a comment.

Next Article in Channel